(0.03%) 5 101.53 points
(0.21%) 38 320 points
(0.06%) 15 937 points
(-1.31%) $82.75
(6.24%) $2.04
(0.07%) $2 348.80
(-0.21%) $27.48
(3.80%) $957.15
(-0.20%) $0.933
(-0.30%) $10.99
(-0.55%) $0.796
(1.67%) $93.41
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 14.14%
Live Chart Being Loaded With Signals
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico...
Stats | |
---|---|
Šios dienos apimtis | 7 745.00 |
Vidutinė apimtis | 50 182.00 |
Rinkos kapitalizacija | 8.96M |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $0 ) 2024-05-01 |
Last Dividend | $1 728.00 ( 2007-03-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.720 |
ATR14 | $0.0400 (0.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Horowitz Joshua | Buy | 16 438 | Common Stock |
2024-04-18 | Horowitz Joshua | Buy | 0 | Common Stock |
2024-04-18 | Horowitz Joshua | Sell | 0 | Common Stock |
2024-04-01 | Higgins Thomas T | Buy | 469 | Common Stock |
2024-04-01 | Higgins Thomas T | Sell | 74 | Common Stock |
INSIDER POWER |
---|
54.21 |
Last 97 transactions |
Buy: 971 558 | Sell: 254 579 |
NeuroMetrix Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
NeuroMetrix Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $5.90M |
Bruto pelnas: | $3.95M (66.89 %) |
EPS: | $-6.27 |
FY | 2023 |
Pajamos: | $5.90M |
Bruto pelnas: | $3.95M (66.89 %) |
EPS: | $-6.27 |
FY | 2022 |
Pajamos: | $8.26M |
Bruto pelnas: | $5.75M (69.65 %) |
EPS: | $-4.90 |
FY | 2021 |
Pajamos: | $8.25M |
Bruto pelnas: | $5.92M (71.75 %) |
EPS: | $-0.342 |
Financial Reports:
No articles found.
NeuroMetrix Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 728.00 | 2007-03-28 |
Last Dividend | $1 728.00 | 2007-03-28 |
Next Dividend | $0 | N/A |
Payout Date | 2007-04-13 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $1 728.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2007 | $1.000 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.083 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.298 | 1.200 | -9.95 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.307 | 1.500 | -4.52 | -6.78 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 16.81 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 14.92 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.396 | 1.500 | 3.36 | 5.03 | [0.2 - 2] |
debtRatioTTM | 0.0112 | -1.500 | 9.81 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 52.63 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.99 | 2.00 | -1.330 | -2.66 | [0 - 30] |
freeCashFlowPerShareTTM | -4.11 | 2.00 | -2.06 | -4.11 | [0 - 20] |
debtEquityRatioTTM | 0.0120 | -1.500 | 9.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.669 | 1.000 | 2.19 | 2.19 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.212 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -25.26 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.275 | 0.800 | -1.497 | -1.198 | [0.5 - 2] |
Total Score | -0.253 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.059 | 1.000 | -0.208 | 0 | [1 - 100] |
returnOnEquityTTM | -0.307 | 2.50 | -2.90 | -6.78 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -4.11 | 2.00 | -1.370 | -4.11 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.99 | 2.00 | -1.330 | -2.66 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0361 | 1.500 | -3.57 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -1.031 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.82 |
NeuroMetrix Inc
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.